Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. (29th June 2020)

• Record Type: Journal Article
• Authors: Titanji, Boghuma K; Farley, Monica M; Mehta, Ashish; Connor-Schuler, Randi; Moanna, Abeer; Cribbs, Sushma K; O'Shea, Jesse; DeSilva, Kathryn; Chan, Bonnie; Edwards, Alex; Gavegnano, Christina; Schinazi, Raymond F; Marconi, Vincent C
• Is Part Of: Clinical infectious diseases. Volume 72:Number 7(2021)
• Page Start: 1247
• Page End: 1250
• Publication Date: 2020-06-29
• Subjects: COVID-19 -- baricitinib -- hyper-inflammation; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa879
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.